New asthma drug candidate IBI3002 begins first human safety tests
NCT ID NCT06947408
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage study tested the safety of a new drug called IBI3002 in 40 healthy volunteers and 20 people with asthma. Participants received either the drug or a placebo, and researchers monitored for side effects. The goal was only to check if the drug is safe enough to study further, not to see if it improves asthma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI3002
- What this could lead to
- If safe, this could lead to larger studies testing whether IBI3002 helps control asthma symptoms.
- What could go wrong
- This is a very early Phase 1 safety trial with only 44 participants. It is not designed to test if the drug works for asthma, and many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China-japan Friendship Hosipital
Beijing, Beijing Municipality, 100192, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?